GNE-9605 NEW
| Price | $56 | $89 | $163 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-30 |
Product Details
| Product Name: GNE-9605 | CAS No.: 1536200-31-3 |
| Purity: 98.55% | Supply Ability: 10g |
| Release date: 2025/07/30 |
Product Introduction
Bioactivity
| Name | GNE-9605 |
| Description | GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM). |
| In vitro | In rats, PKGNE-9605 administered orally at a dose of 1 mg/kg exhibited a total plasma clearance rate of 26 mL/min/kg, achieving an oral bioavailability of 90%. In BAC transgenic mice models expressing the human LRRK2 G2019S mutation associated with Parkinson's disease, GNE-9605, administered intraperitoneally at doses of 10 and 50 mg/kg, was able to inhibit the autophosphorylation of LRRK2 at Ser1292. |
| In vivo | In vitro human MDR1 permeability data indicate that GNE-9605 exhibits favorable brain penetration in higher organisms. In biochemical (Ki: 2.0 nM) and cellular (IC50: 19 nM) assays, GNE-9605 demonstrates potent inhibitory activity against LRRK2. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 82 mg/mL (182.29 mM), Sonication is recommended. Ethanol : 10 mg/mL (22.23 mM), Sonication is recommended. |
| Keywords | Parkinson's disease | oral bioavailability | LRRK2 Ser1292 | LRRK2 | Leucine-rich repeat kinase 2 | Inhibitor | inhibit | GNE-9605 | GNE9605 | GNE 9605 | autophosphorylation |
| Inhibitors Related | IKK 16 | PFE-360 | GNE0877 | CZC-25146 | GSK2578215A | CZC-54252 hydrochloride | GNE-7915 | EB-42486 | LRRK2 inhibitor 1 | LRRK2-IN-7 | LRRK2-IN-1 | CCG-1423 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Kinase Inhibitor Library | Glutamine Metabolism Compound Library | Anti-Parkinson's Disease Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY